Arecor Therapeutics PLC Arecor Granted Key U.S Patent (4505X)

TIDMAREC

RNS Number : 4505X

Arecor Therapeutics PLC

26 April 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES

- Endorses potential of proprietary Arestat (TM) platform technology to invent novel, enhanced therapeutics in $210 billion monoclonal antibody market

   -      Further strengthens Group's extensive patent portfolio 

Cambridge, UK, 26 April 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11608357) protecting a novel formulation platform that enables the development of enhanced monoclonal antibodies.

Monoclonal antibodies represent a key segment of the biopharmaceuticals market, valued at $210 billion in 2022 and are projected to see a compound annual growth rate (CAGR) of 11.04% from 2023 to 2030(1) .

There has been a strong drive towards patient-centricity in the biopharmaceutical industry, particularly in the development of convenient dosage forms. However, achieving such desirable dosage forms is often hampered by insufficient stability or high viscosity of monoclonal antibodies when formulated using conventional formulation approaches. To address this problem Arecor has developed a number of highly innovative, proprietary formulation platforms enabling superior stability of monoclonal antibodies under various stress conditions. This US patent protects one of these proprietary formulation platforms within the Group's broader Arestat(TM) technology.

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented : "Whilst a number of novel therapeutic modalities are being developed, such as complex engineered protein constructs or mRNA therapies, monoclonal antibodies continue to dominate the biopharmaceutical field. Safety and efficacy are obviously the key criteria for any new product, but the increasing focus on patient-centricity and improved convenience of delivery often requires superior product stability which is often difficult to achieve using conventional approaches. Our highly innovative formulation technology addresses these challenges and, when applied, we are able to develop enhanced novel pharmaceutical products, both for our growing partnerships with Pharma companies and in our proprietary pipeline. This US patent is a very important addition to our IP portfolio, protecting a formulation design space that enables monoclonal antibodies with superior stability."

Arecor leverages its Arestat(TM) technology in partnerships with leading pharmaceutical and biotechnology companies to deliver enhanced products under a technology licensing model, as well as developing an internal portfolio of proprietary products in diabetes and other indications. As part of this strategy Arecor continues to invest in a strong patent portfolio to protect the Arestat(TM) platform, currently comprising 38 patent families and >75 granted patents.

References

   1.   https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market 

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: [phone] 
                                             Email: [e-mail] 
 
 Susan Lowther, Chief Financial Officer     Tel: [phone] 
                                             Email: [e-mail] 
 
 Mo Noonan, Communications                  Tel: [phone] 
                                             Email: [e-mail] 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: [phone] 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: [phone] 
  Gray                                       Email: [e-mail] 
 

Notes to Editors

About Arestat(TM)

Arecor's Arestat(TM) technology enables superior product profiles across a broad range of therapies, including various types of biopharmaceuticals and specialty hospital products. In addition to its internal portfolio of superior proprietary products in diabetes and other indications, Arecor leverages the Arestat(TM) technology in partnerships with leading pharmaceutical and biotechnology companies to deliver enhanced products under a technology licensing model .

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio .

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAELSAFDDEAA

(END) Dow Jones Newswires

April 26, 2023 02:00 ET (06:00 GMT)